Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients

INTRODUCTION: As patients with rheumatoid arthritis (RA) receive treatment with anti-tumour necrosis factors over several years, it is important to evaluate their long-term safety and efficacy. The objective of this study was to examine the safety and benefits of certolizumab pegol (CZP)+methotrexat...

Descripción completa

Detalles Bibliográficos
Autores principales: Smolen, Josef S., van Vollenhoven, Ronald, Kavanaugh, Arthur, Strand, Vibeke, Vencovsky, Jiri, Schiff, Michael, Landewé, Robert, Haraoui, Boulos, Arendt, Catherine, Mountian, Irina, Carter, David, van der Heijde, Désirée
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565002/
https://www.ncbi.nlm.nih.gov/pubmed/26353833
http://dx.doi.org/10.1186/s13075-015-0767-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565002/
https://www.ncbi.nlm.nih.gov/pubmed/26353833
http://dx.doi.org/10.1186/s13075-015-0767-2

Ejemplares similares